Emcure Pharmaceuticals has filed preliminary documents (DRHP) with SEBI for its IPO of over Rs 1,100 crore. New shares worth Rs 1,100 crore will be issued through this IPO, while 18,168, 365 equity shares will be sold through offer for sale. It also includes equity shares sold by promoters. The size of the issue will be more than Rs 1,100 crore.
The company earned a profit of Rs 418.5 crore during the financial year 2020-21.
During the last financial year (2020-21), the company has made a profit of Rs 418.5 crore. The company is making profit for the last three financial years. During the last financial year, the company had achieved a revenue of Rs 6091 crore. 50% of the IPO is reserved for QBIs. 35 per cent is reserved for retail investors and 15 per cent for NIIs. Post listing, it will join the league of Abbott India, Alkem Laboratories, Biocon Limited, Cipla, Dr Reddy’s Laboratories, and Torrent Pharmaceuticals.
JhunJhunwala Portfolio: Rakesh JhunJhunwala bet in the shares of this group companies, the price increased by 135 percent in a single year
Emcure Pharmaceuticals 12th largest pharma company in the country
Emcure Pharmaceuticals is the 12th largest pharma company in the country. The company does the work of making new medicines, their production and marketing. It markets medicines in many countries and has a presence in 70 countries. Under the IPO, promoters Satish Mehta and Sunil Mehta will sell 20.30 lakh and 2.5 lakh shares under offer for sale, respectively. BC Investment IV will sell 99.5 lakh shares. It is a unit of American private investment company Bain Capital. Before the IPO, Emcure can bring a pre-placement of Rs 200 crore.